Form 4: Vertex Pharmaceuticals CEO Reshma Kewalramani Sells 15,198 Shares
SEC Filing
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, sold 15,198 shares of common stock at a price of $515 per share on November 8, 2024, according to a recent SEC Form 4 filing.
Summary
- Reshma Kewalramani, the CEO and President of Vertex Pharmaceuticals, sold 15,198 shares of common stock on November 8, 2024.
- The transaction was executed at a price of $515 per share.
- Following the transaction, Dr. Kewalramani directly owns 75,772 shares of Vertex Pharmaceuticals.
- The sale was conducted under a pre-arranged trading plan (Rule 10b5-1) established on February 7, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine transaction under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific inside information.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 02/07/2024 | Date of entry into Rule 10b5-1 trading plan |
| 11/08/2024 | Date of stock sale transaction |
| 11/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.